Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best healthcare stocks to buy for 2026. On January 20, RBC Capital reiterated an Outperform rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) but cut the price target to $465 from $500.

The new price outlook comes on Alnylam Pharmaceuticals announcing strategic priorities for the year, including achieving revenue of $5.1 billion, exceeding the consensus estimate of $4.7 billion. While there have been concerns about November performance, it was mostly affected by one-time factors, including fewer selling days. In the long term, the company is targeting 25% compound annual growth rate through 2030, which aligns with revenue of $11.2 billion.

On the other hand, Cantor Fitzgerald has reiterated its Neutral rating on Alnylam Pharmaceuticals. The cautious outlook comes on Amvuttra cardiomyopathy sales slowing down in November but rebounding in December. The company expects Amvuttra’s net price to decline by mid-single digits in 2026. The sales patterns and pricing strategy provide context for the research firm’s neutral stance.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) develops innovative medicines using RNA interference (RNAi) to “silence” disease-causing genes, acting as a pioneer in this revolutionary field to create treatments for rare and prevalent genetic, metabolic, cardiovascular, and neurological diseases.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.